Cat# : THA-0122
Cat#: | THA-0122 |
Product Name: | Trastuzumab deruxtecan |
Description: | Trastuzumab deruxtecan is an antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. |
Sequences: | Not Available |
Molecular Weight: | Not Available |
Introduction: | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019. |
Purity: | >99% by SDS-Page and HPLC analysis |
Formula: | Not Available |
Appearance: | Not Available |
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © 2024 Creative BioMart. All Rights Reserved.